Brain aging is associated with lower production of circadian clock proteins, which synchronize biological processes to light and dark cycles. In Alzheimer’s and other neurodegenerative diseases, circadian dysfunction is commonly observed.
Several weeks ago, the Cure Alzheimer’s Fund (CAF) Executive Committee and staff met with the members of our Research Consortium in Chicago.
Adding to its impressive roster of many of the nation’s leading scientists, the Cure Alzheimer’s Fund Research Consortium is pleased to announce its two newest members, Eric Schadt, Ph.D. (left), and Rick Huganir, Ph.D. (right).
The Research Consortium develops and updates a “roadmap for research” for the most effective and efficient route to slowing, stopping and/or reversing Alzheimer’s disease, the most common form of dementia. Members research their own projects and recruit others whose work will hasten the development of effective therapies.
Washington (November 7, 2013) – As the country commemorates November as National Alzheimer’s Awareness month, Senator Edward J. Markey (D-Mass.) has been announced as the new Senate co-chair of the Bipartisan Congressional Task Force on Alzheimer’s Disease. Senator Markey was co-chair of the Task Force with Rep. Chris Smith (R-N.J.) when he served in the House of Representatives. While in the House, then-Rep. Markey co-authored the National Alzheimer’s Project Act, which mandated the development of a first-ever comprehensive National Plan to Address Alzheimer’s Disease.
Our congratulations to Dr. Thomas C. Sϋdhof of Stanford University, a member of Cure Alzheimer’s Fund's Research Consortium, who joins Randy Scheckman of the University of California, Berkeley and James E. Rothman of Yale University in winning the Nobel Prize in Physiology or Medicine as announced today.
"Desperate For A Cure: The Search For New Alzheimer's Treatments", a new five-part series by NPR's Sean Corcoran, aired this week on WCAI and will air again next week on WGBH in Boston.
Charlie Collier is a former senior philanthropic advisor for Harvard University and author of the groundbreaking book Wealth in Families. In 2008, at age 60 he was diagnosed with early-onset Alzheimer's disease. Since then, Charlie has devoted himself to speaking out about his condition, and encouraging others to do the same. "I am trying to get people to talk and ask me hard questions," he says.
In a paper just published in the prestigious journal Neuron, Harvard Medical School/Mass General Hospital Geneticist Dr. Rudy Tanzi, together with lead author, Dr. Jaehong Suh and their team, identified two rare mutations in the human gene called "ADAM10" that lead to the most common, late-onset variant of Alzheimer's. Tanzi's research suggests that the ADAM10 gene makes an enzyme called alpha-secretase, which cleaves the Amyloid Precursor Protein (APP) to prevent the formation of beta-amyloid, the toxic protein that triggers brain pathology in Alzheimer's disease.
Drs. Sam Gandy and Scott Noggle have received an NIH grant to gain new insights and identify potential therapies for Alzheimer’s disease.
When author David Shenk wrote The Forgetting, Alzheimer's: Portrait of an Epidemic, he gave us the big picture of Alzheimer's disease. His latest project, "Living With Alzheimer's", a series of four short films created with funding from the MetLife Foundation and in partnership with Cure Alzheimer's Fund, brings us to the personal level.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.